Hinge Health
Combines motion tracking, wearable therapy, and clinicians for employer-sponsored musculoskeletal care.
Something off on this page? Send us feedback.
Profile
Delivers digital musculoskeletal care through AI-powered motion tracking, Enso electrical nerve stimulation, and clinician-supported programs. Primary clients are self-insured employers that make access available to eligible employees and adult dependents, combining software, wearable hardware, and care teams in one service.
Delivers digital musculoskeletal care for joint and muscle pain through an integrated platform serving primarily self-insured employers. Eligible employees and adult dependents receive programs that combine AI-powered motion tracking, Enso electrical nerve stimulation, and support from licensed physical therapists, physicians, and board-certified health coaches.
Care spans treatment and prevention rather than a narrow telehealth visit, joining software, wearable hardware, and clinical teams in one service. The founder-led company operates from San Francisco after moving there from London.
Access is tied to employers making the platform available as a workforce benefit. Delivery relies on proprietary technology, the Enso wearable, and licensed care staff working together.
Company facts
Key statistics
Year to date +91.7% · Average volume (30d) 1.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 10, 2026 | Truist Financial | Target | $85 | $112 | |
| Aug 5, 2026 | Evercore ISI | Reiterate | Outperform | $45 | $105 |
| Aug 5, 2026 | RBC Capital | Reiterate | Outperform | $75 | $110 |
| Aug 5, 2026 | Canaccord Genuity | Target | $100 | $105 | |
| Aug 5, 2026 | Stifel Nicolaus | Target | $90 | $96 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.62 | $0.59 | −4.1% | $201.5M | $212.8M | +5.6% | +1.73% |
| May 5, 2026Q1 FY26 | $0.39 | $0.45 | +15.4% | $172.2M | $182.3M | +5.9% | +10.23% |
| Feb 10, 2026Q4 FY25 | $0.04 | $0.49 | +1,125.0% | $156.7M | $170.7M | +9.0% | +17.53% |
| Nov 4, 2025Q3 FY25 | $0.24 | $0.34 | +41.7% | $156.8M | $154.2M | −1.6% | −15.06% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $123.8M | $139.1M | $154.2M | $170.7M | $182.3M | $212.8M | |
| Gross profit | $100.2M | $97.8M | $126.2M | $144.2M | $154.2M | $183.9M | |
| Operating income | $13.1M | −$580.7M | −$6.1M | $27.3M | $32.1M | $40.4M | |
| Net income | $121.3M | −$575.7M | −$1.8M | $32.1M | $35.1M | $43.7M | |
| Diluted EPS | $1.55 | −$7.38 | −$0.02 | $0.37 | $0.41 | $0.53 | |
| Gross margin | 80.9% | 70.3% | 81.9% | 84.4% | 84.6% | 86.4% | |
| Operating margin | 10.6% | -417.5% | -4.0% | 16.0% | 17.6% | 19.0% |
Fiscal years (4-quarter sums)FY24 $390.4M · FY25 $587.9M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $389.4M · Total debt $5.9M · Total assets $827.4M · Shareholders' equity $344.3M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 77.38M · Float —
Float — provider float is below the insider stake.
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Daniel Antonio Perez · director, 10 percent owner, officer: CEO & Co-Founder | 25.04M | 32.36% | Form 4 | Jul 29, 2026 |
| Daniel Antonio Perez | 10.37M | 15.70% | 13G | Feb 13, 2026 |
| Atomico Advisors IV, Ltd. · 10 percent owner | 6.71M | 8.68% | Form 4 | May 27, 2025 |
| Gabriel M.I. Mecklenburg · director, other: Exec. Chairman & Co-Founder | 5.09M | 6.58% | Form 4 | Aug 6, 2026 |
| Bessemer Venture Partners X L.P. · 10 percent owner | 3.38M | 4.37% | Form 4 | Nov 20, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Elliott Robinson | director | 0 | |
| Aug 21, 2026 | James Pursley | officer: President | −33,000 | $88.05 |
| Aug 20, 2026 | Kristina M. Leslie | director | −1,200 | $88.23 |
| Aug 19, 2026 | Elliott Robinson | director | 0 | |
| Jul 9, 2026 | Insight Holdings Group, LLC | 10 percent owner | −176,352 | $90.18 |
Peers
- Omada Health
Direct virtual MSK and employer-benefits platform rival
- DarioHealth
Digital MSK pain platform competing for employer and health-plan clients
- U.S. Physical Therapy
In-person physical therapy and workplace injury-prevention alternative
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Hinge Health | $86.00 | −1.52% | $6.76B | 67.9 | 32.3 | 9.4 | +53.0% |
| Omada Health | $23.82 | +0.64% | $1.41B | 376.0 | 77.8 | 4.5 | +43.1% |
| DarioHealth | $6.77 | +4.15% | $49.5M | 9.8 | — | 2.4 | −3.6% |
| U.S. Physical Therapy | $78.63 | +0.05% | $1.20B | 462.5 | 25.3 | 1.5 | +30.4% |
| Median | 376.0 | 51.5 | 2.4 | +30.4% |